182 related articles for article (PubMed ID: 23013664)
21. [Tracers in oncology - preclinical and clinical evaluation].
Krause BJ; Schwarzenböck S; Schwaiger M
Nuklearmedizin; 2010; 49 Suppl 1():S41-5. PubMed ID: 21152689
[TBL] [Abstract][Full Text] [Related]
22. [Detection of tumors in the central zone of the prostate with 11C-Choline PET/CT].
Garcia JR; Soler M; Moragas M; Ponce A; Moreno C; Riera E
Rev Esp Med Nucl Imagen Mol; 2014; 33(2):112-4. PubMed ID: 24119550
[TBL] [Abstract][Full Text] [Related]
23. Comparison of meta-analyses among elastosonography (ES) and positron emission tomography/computed tomography (PET/CT) imaging techniques in the application of prostate cancer diagnosis.
Ouyang Q; Duan Z; Lei J; Jiao G
Tumour Biol; 2016 Mar; 37(3):2999-3007. PubMed ID: 26415734
[TBL] [Abstract][Full Text] [Related]
24. Initial prostate cancer diagnosis and disease staging--the role of choline-PET-CT.
Mapelli P; Picchio M
Nat Rev Urol; 2015 Sep; 12(9):510-8. PubMed ID: 26260884
[TBL] [Abstract][Full Text] [Related]
25. 18F-Choline, 11C-choline and 11C-acetate PET/CT: comparative analysis for imaging prostate cancer patients.
Brogsitter C; Zöphel K; Kotzerke J
Eur J Nucl Med Mol Imaging; 2013 Jul; 40 Suppl 1():S18-27. PubMed ID: 23579863
[TBL] [Abstract][Full Text] [Related]
26. Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer.
Scher B; Seitz M; Albinger W; Tiling R; Scherr M; Becker HC; Souvatzogluou M; Gildehaus FJ; Wester HJ; Dresel S
Eur J Nucl Med Mol Imaging; 2007 Jan; 34(1):45-53. PubMed ID: 16932935
[TBL] [Abstract][Full Text] [Related]
27. 11C-choline positron emission tomography in prostate cancer: primary staging and recurrent site staging.
Yoshida S; Nakagomi K; Goto S; Futatsubashi M; Torizuka T
Urol Int; 2005; 74(3):214-20. PubMed ID: 15812206
[TBL] [Abstract][Full Text] [Related]
28. Imaging prostate cancer with 11C-choline PET/CT.
Reske SN; Blumstein NM; Neumaier B; Gottfried HW; Finsterbusch F; Kocot D; Möller P; Glatting G; Perner S
J Nucl Med; 2006 Aug; 47(8):1249-54. PubMed ID: 16883001
[TBL] [Abstract][Full Text] [Related]
29. PET/CT in prostate cancer: non-choline radiopharmaceuticals.
Castellucci P; Jadvar H
Q J Nucl Med Mol Imaging; 2012 Aug; 56(4):367-74. PubMed ID: 23013666
[TBL] [Abstract][Full Text] [Related]
30. [Pitfalls with 18F-choline PET/CT in patients with prostate cancer].
García Vicente AM; Núñez García A; Soriano Castrejón AM; Jiménez Londoño GA; Cordero García JM; Palomar Muñoz A
Rev Esp Med Nucl Imagen Mol; 2013 Jan; 32(1):37-9. PubMed ID: 23177342
[TBL] [Abstract][Full Text] [Related]
31. The value of 18F-choline PET/CT in patients with elevated PSA-level and negative prostate needle biopsy for localisation of prostate cancer.
Igerc I; Kohlfürst S; Gallowitsch HJ; Matschnig S; Kresnik E; Gomez-Segovia I; Lind P
Eur J Nucl Med Mol Imaging; 2008 May; 35(5):976-83. PubMed ID: 18188560
[TBL] [Abstract][Full Text] [Related]
32. Nuclear medicine studies of the prostate, testes, and bladder.
Jana S; Blaufox MD
Semin Nucl Med; 2006 Jan; 36(1):51-72. PubMed ID: 16356796
[TBL] [Abstract][Full Text] [Related]
33. [11C]choline PET for the intraprostatic tumor characterization and localization in recurrent prostate cancer after EBRT.
Rybalov M; Breeuwsma AJ; Pruim J; Leliveld AM; Rosati S; Veltman NC; Dierckx RA; De Jong IJ
Q J Nucl Med Mol Imaging; 2012 Apr; 56(2):202-8. PubMed ID: 22402821
[TBL] [Abstract][Full Text] [Related]
34. [The (11C) acetate positron emission tomography in prostatic carcinoma. New prospects in metabolic imaging].
Hautzel H; Müller-Mattheis V; Herzog H; Roden W; Coenen HH; Ackermann R; Müller-Gärtner HW; Krause BJ
Urologe A; 2002 Nov; 41(6):569-76. PubMed ID: 12524944
[TBL] [Abstract][Full Text] [Related]
35. 11C- or 18F-Choline PET/CT for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer.
Mapelli P; Incerti E; Ceci F; Castellucci P; Fanti S; Picchio M
J Nucl Med; 2016 Oct; 57(Suppl 3):43S-48S. PubMed ID: 27694171
[TBL] [Abstract][Full Text] [Related]
36. [First experience of using positron emission tomography with 11C-choline in prostate cancer (PC)].
Granov AM; Tiutin LA; Ryzhkova DV; Shkol'nik MI; Andabekov TT; Mostova MI; Shatik SV; Kostenikov NA; Zaĭtsev VV; Tlostanova MS; Stanzhevskiĭ AA; Panfilenko AA; Arzumanov AA; Metelëv VV; Iliushchenko IuR
Vopr Onkol; 2013; 59(4):460-4. PubMed ID: 24032219
[TBL] [Abstract][Full Text] [Related]
37. [Visualization of prostate cancer with 11C-choline positron emission tomography (PET): localization of primary and recurrent prostate cancer].
Kanda T; Nakagomi K; Goto S; Torizuka T
Hinyokika Kiyo; 2008 May; 54(5):325-32. PubMed ID: 18546855
[TBL] [Abstract][Full Text] [Related]
38. Recent developments in urologic oncology: positron emission tomography molecular imaging.
Bouchelouche K; Oehr P
Curr Opin Oncol; 2008 May; 20(3):321-6. PubMed ID: 18391633
[TBL] [Abstract][Full Text] [Related]
39. Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline.
Jadvar H
J Nucl Med; 2011 Jan; 52(1):81-9. PubMed ID: 21149473
[TBL] [Abstract][Full Text] [Related]
40. Update on positron emission tomography for imaging of prostate cancer.
Kitajima K; Murphy RC; Nathan MA; Sugimura K
Int J Urol; 2014 Jan; 21(1):12-23. PubMed ID: 23991644
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
